Despite these improvements, TP53 aberrations, particularly multi-hit mutations, remain negative prognostic factors for both treatment-naïve and relapsed or refractory CLL patients receiving BTKi therapy or venetoclax-based time-limited treatments [12, 35, 182]. The gene discussed is TP53; the disease is B-cell chronic lymphocytic leukemia.